Finance entity
markets is the sole category represented across all 1 tracked stories. UCB Biopharma is most often covered alongside Adalimumab, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 4 original sources each against 2.7 for the same window.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. UCB Biopharma is most often covered alongside Adalimumab, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 4 original sources each against 2.7 for the same window. Their average consequence score of 6 runs above the beat's 5.8 for that window. We currently track 1 Finance story that mention UCB Biopharma, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 174 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UCB Biopharma. Shared-story counts are live from our verified record — not editorial picks.
The Juvenile Idiopathic Arthritis (JIA) market is projected to expand at a 5.6% CAGR through 2036, reaching multi-billion dollar valuations driven by advanced biologic therapies. Major pharmaceutical players including Bristol-Myers Squibb and Novartis are positioned to capture significant share with next-generation treatments.
UCB Biopharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
